Repros Therapeutics reported additional topline results for study ZA-302, the second pivotal efficacy study for Androxal. The results of both pivotal studies, ZA-301 and ZA-302, have met the SPA co-primary endpoints as defined by the FDA, the company said. Study ZA-302 had no detected site anomalies. The company said it is completely satisfied that all data entered into the data base for study ZA-301 will pass any scrutiny the FDA chooses to apply. The company said, "We are confident in the reliability of our results and the positive outcomes of our two pivotal clinical trials. Our style with the investment community has always been direct and honest and we are happy to provide this additional data for investor review."